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Abstract 
Glucose lowering drugs have been available for 
clinical use for over the past 60 years or so with the last 
2 decades seeing a significant number of new agents 
being developed making treatment increasingly complex 
and also somewhat  controversial.  This stems from the 
fact that while it is now known that patients with 
diabetes have an increased risk for cardiovascular 
disease and mortality there are mounting concerns with 
regards to the cardiovascular effects of certain 
antihyperglycemic agents leading to uncertainties when 
it comes to drug prescription.  This has left many 
clinicians perplexed with respect to optimal strategies 
for management for management of such patients 
leading to many regulatory bodies to issue 
recommendations for antihyperglycimic therapy in 
adults with type 2 diabetes. These all uniformly advocate 
an individualised approach, keeping in mind each 
patients’ unique health profile (such as age and weight) 
and their cardiovascular risk factors vis-a-vie the 
specific attributes, side effects and adverse effects of 
each antihyperglycemic agent.   This article will focus 
on the ten major categories of diabetic therapies looking 
specifically at their mode of action, safety profile as well 
as key trial data and where possible the long-term 
outcome studies for each class. 
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Introduction 
The last few decades have seen a considerable 
increase in the therapeutic armamentarium for the 
management of patients with type 2 diabetes (T2 DM). 
As the incidence and prevalence of diabetes continues to 
increase worldwide so has been the struggle to find the 
ideal antihyperglycemic agent which is cost-effective at 
achieving and maintaining near-normal blood glucose 
levels, but also has a favourable safety profile, has good 
tolerability with limited side effects and possibly also 
exerting positive effects on surrogate markers of 
cardiovascular risk.1-3 This stems from the fact that 
patients with T2 DM have an increased risk of 
cardiovascular morbidity and mortality and while data 
from recent key trials have shown that tight glycaemic 
control results in sustained reductions on microvascular 
event rates (including nephropathy, neuropathy and 
retinopathy), strict and aggressive blood glucose control 
does not necessarily exert beneficial effects on 
macrovascular events and may actually increase 
mortality.2-9 Thus, keeping in mind that the ultimate aim 
for diabetic patients would be to reduce this excess 
cardiovascular risk one should look at other 
characteristics of anithyperglycemic agents independent 
of glycemic control which may influence cardiovascular 
outcomes in such patients.2  In fact over the past few 
years, many questions have arisen regarding the 
cardiovascular safety or otherwise of drugs used to treat 
diabetes. This occurred following the results of a highly 
publicized meta-analysis in 2007 concerning the 
thiazolidinedione rosiglitazone.  Here the authors 
demonstrated a significant increase in risk of myocardial 
infarction (odds ratio 1.43) and death from 
cardiovascular (CV) causes (odds ratio 1.46) with 
rosiglitazone use fuelling a lot of controversial issues 
with respect to prescribing this drug as well as 
stimulating the debate on whether diabetes drugs should 
have long-term trials showing cardiovascular safety 10-
11).  This eventually led the U.S. Food and Drug 
Administration (FDA) to issue a ‘boxed warning in the 
drug's labelling about potential increased risk for heart 
attacks’.  Furthermore in 2008 it also issued new 
recommendations with respect to evaluation of 
cardiovascular risk in the premarketing and 
postmarketing assessment of novel antidiabetic therapy 
defined as the upper bound of the 95% Confidence 
Interval for major adverse cardiovascular events 
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(MACE) of < 1.3 leading to profound changes to the 
way new antidiabetic drugs are developed.6,12-15  Keeping 
all this in mind, this article will focus on the ten major 
classes of drugs used to treat T2DM focussing on their 
mode of action, their safety profile as well as key trial 
data and where possible the long-term outcome studies 
for each class. 
 
Sulphonylureas 
Sulphonylureas (SU) have been in use for the past 
50 odd years making them the oldest class of oral 
antihyperglycemic agents.  They are the major insulin 
secretagogues and their mode of action is well 
understood.  These exert their effect by binding to the 
adenosine triphosphate (ATP)-sensitive potassium 
channels situated on the Beta (β)-cells inhibiting 
potassium efflux leading to subsequent depolarization of 
the β-cell, which ultimately results in insulin secretion.16-
19 Interestingly these ion channels are also present in 
cardiac myocytes and have been implicated for the 
adverse effects of SU on the heart.2  There are a number 
of agents available in this class with the major difference 
between them being in their side-effect profile and their 
duration of action. SU reduce HbA1c by around -0.9 to -
2.5% and have thus been advocated for use as 
monotherapy and first line agents in non-obese 
individuals or in combination with other 
antihyperglycemic drugs.1,16-18  The well-known side-
effects of these drugs include the risk of hypoglycaemia 
and weight gain. Much of our knowledge on SU comes 
from the United Kingdom Prospective Diabetes Study 
(UKPDS). This landmark multicentre study which was 
carried out over 20 years between 1997 and 1999 in the 
UK randomised more than 4000 newly diagnosed type 2 
diabetic patients to either intensive treatment with 
insulin or SU (with a small subset of overweight patients 
being given metformin instead) or to conventional 
therapy consisting of dietary and lifestyle modification. 
Patients randomised to intensive treatment with 
SU/insulin showed a lower risk of microvascular 
complications (25%) then conventional therapy as well 
as a non-significant (16%) reduced risk of myocardial 
infarction (p=0.052), however, this was at the expense of 
significantly greater weight gain which however was 
less than in those treated with insulin. Hypoglycaemic 
episodes were more frequent in the intensively treated 
group however patients assigned to SU treatment 
exhibited lower rates of both minor and major 
hypoglycaemia when compared to those on insulin 
therapy.18-22 On the other hand, the specific effects of SU 
therapy on CV outcomes is still conflicting. Previous 
studies (including the University Group Diabetes 
Program [UGDP] which used the older generation SU 
tolbutamide) have implied that SU treatment may be 
associated with adverse CV effects.23  Conversely  in the 
UKPDS, this suggestion was not reproducible as none of 
the SU used showed an increased rate of adverse CV 
outcomes.22, 24 Furthermore, in the 10-year post trial 
follow-up of the UKPDS, the sulphonylurea-insulin 
group continued to have significant risk reductions for 
any diabetes-related end point, microvascular disease, 
all-cause mortality as well as significantly reduced risk 
for myocardial infarction despite convergence in glucose 
control between the different treatment arms after one 
year.21, 22  This implies a legacy-effect and that early 
aggressive glycaemic control led to sustained benefits 
after 10 years of follow-up with respect to microvascular 
disease with the added benefit of reduced macrovascular 
events which were not seen during the interventional 
phase of the trial.19,21-22,24 Recently  meta-analysis 
looking at cohort and case-control studies showed that 
SU monotherapy or in combination treatment was 
associated with higher all-cause and cardiovascular 
mortality risks when compared to patients receiving non-
SU treatment.    The authors explain that the potential 
causes for this could be due to four specific effects of 
SU therapy namely hypoglycaemia, weight gain, 
increased proinsulin release and activation of SU 
receptors on myocardial muscle cells. However they 
caution that these results should be interpreted carefully 
not only because data from randomised controlled trials 
was missing but also because the data had high treatment 
group heterogeneity.25 Interestingly these findings were 
also echoed in another meta-analysis by an Italian group 
of authors published in the same year.26 Another 
important issue that emerges from the UKPDS is the 
effect of SU on β-cell function. The widely held view 
that SU are associated with loss of β-cell function is not 
reproducible in this study as it was found that the 
percentage mean β-cell function decreased in all groups 
irrespective of the treatment modality used19 Thus while 
treatment with SU has been established over the last 5 
decades or so, they should be used judiciously within a 
multi-factorial risk reduction strategy and treatment 
tailored according to the patients characteristics (such as 
age and weight), presence of co-morbidities and other 
risk factors 25.  
 
Biguanides 
The widely available drug in this class is metformin  
and its use has been around for the past five decades or 
so,  thus establishing itself as a safe and cost-effective 
glucose lowering agent such that most guidelines now 
uniformly advocate its use as a first line agent in the 
management of overweight or obese type 2 diabetics1 ).  
Metformin has been classified as an insulin sensitizer 
but its mode of action has only recently been 
understood.  This involves activation of an adenosine 
monophosphate (AMP)- kinase enzyme which plays an 
important part in carbohydrate and lipid metabolism as 
well as inhibition of mitochondrial respiration leading to 
inhibition of hepatic glucose production, increased 
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glucose uptake in contracting muscle, increased fatty-
acid oxidation, decreased lipolyisis and enhanced insulin 
sensitivity without the undesirable side effects of weight 
gain or hypoglycaemia.17, 1, 27-29 Metformin, when used as 
monotherapy has been associated with a reduction in 
glycated haemoglobin (HbA1c) of between -1.1% to -
3% 18(). Two important clinical trials using metformin 
are the Diabetes Prevention Program (DPP) and the 
UKPDS.  In the DPP, metformin showed a 31% 
reduction in diabetes incidence over approximately 3 
years and this effect was sustained in the ten-year follow 
up of the DPP suggesting that metformin is a good long-
term strategy for diabetes prevention.27,29-30 In the 
UKPDS trial, patients randomised to treatment with 
metformin achieved similar FPG and HbA1c levels to 
those randomised to treatment with insulin or 
sulfonylurea however with the added benefit of no 
weight gain and reduced risk of hypoglycaemia31 ). With 
respect to complications, in the UKPDS metformin was 
associated with a 32% lower risk of developing any 
diabetes related end-point, a 36% lower risk of all-cause 
mortality, a 42% risk reduction for diabetes-related 
death and 39% lower risk of myocardial infarction then 
in the conventionally treated group.27-31 Moreover, these 
results were sustained in the 10 year follow-up study 
albeit differences in glycemic control were blunted after 
the first year of follow-u 21, 28 This study thus implies 
that metformin has numerous advantages notably 
amelioration of macrovascular risk that make it the ideal 
first choice treatment in obese diabetics 27,30 ). 
Metformin has also been associated with a reduced 
incidence of the metabolic syndrome (by 17% when 
compared with placebo) in the DPP.29 Moreover several 
meta-analysis have also shown that metformin exerts 
favourable effects on surrogate markers of CV risk with 
reduction in fasting and postprandial plasma 
triglycerides, low density lipoprotein (LDL)-cholesterol, 
and free fatty acids.18, 28 Another important landmark of 
metformin is its effects on heart failure. It has been 
shown that metformin monotherapy is associated with 
reduced mortality rates as well as lower hospitalization 
rates in subjects with heart failure when compared with 
other anti diabetic drugs.28, 32 Another important feature 
of metformin is its role in fertility in women with 
Polycystic Ovary Syndrome (PCOS) with recent studies 
showing that therapy with metformin significantly 
improves pregnancy rates as well as live-birth rates.28 
Metformin has also been associated with anti-neoplastic 
properties due to its action on AMPK which leads to 
inhibition of the mammalian Target Of Rapamycin 
(mTOR) causing inhibition of the cell cycle.28 
Metformin’s anti-neoplastic effects range from solid to 
haematological malignancy, however further research is 
required in this field.  The main documented side effects 
of metformin include gastrointestinal adverse effects, 
notably bloating, diarrhoea, flatulence, and abdominal 
cramps.1,27-28 These are usually off-set by introducing 
metformin at a low dose and increasing it gradually over 
a few days to weeks. The risk of lactic acidosis is 
actually very rare with studies showing that this event 
may occur in situations associated with a tendency for 
hypoxia or acidosis – such as sepsis or acute heart 
failure.27,29 Metformin has also been associated with 
vitamin B deficiency, however, this too is a rare event 
but should be sought in patients with macrocytic 
anaemia, peripheral neuropathy or cognitive 
impairment.27,29 With respect to long-term outcome 
studies on metformin, the UKPDS trial and its 10-year 
follow up show convincing evidence that metformin is 
as good as sulfonylureas or insulin on glycemic control 
and it was the only drug to show a reduction in 
myocardial infarction rates which persisted in the 10-
year post trial follow-up. Meta-analyses have shown that 
the benefits of metformin on cardiovascular risk were 
observed in those trials compared with placebo or no 
therapy (CI 0.64-0.98, p=0.031) but disappeared when 
compared to active comparator trials suggesting that the 
cardiovascular protection is due to the improved 
glycemic control.22, 33 Taking all this into account 
metformin is still considered a safe drug and given its 
low cost is an ideal agent for first line treatment in type 
2 diabetes.  
 
Thiazolidinediones 
Thiazolidinediones (TZDs) are insulin sensitizing 
agents and work primarily by activating the peroxisome 
proliferator-activated receptor (PPAR)-γ leading to 
increased transcription of genes involved in glucose and 
lipid metabolism as well as energy balance. One of these 
is the glucose transporter GLUT-4 which in the presence 
of insulin is associated with increased glucose uptake. 
PPAR-γ is also expressed in adipocytes and endocrine 
signalling from adipocytes results in enhanced 
adipognensis and decreased fat breakdown (mediated by 
signalling factors such as free fatty acids and TNF-α) 
leading to a reduction in liver fat and improvement in 
insulin sensitivity in liver and muscle.1, 18, 22 The two 
available TZDs are rosiglitazone and pioglitazone 
however, concerns associating rosiglitazone with 
increased risk of ischemic cardiac events (as already 
mentioned in the  introduction of this article) led to the 
withdrawal from marketing authorisation of this drug 
within the EU in 2010 by the European Medicines 
Agency (EMA) and highly restricted access within the 
States by the FDA.1, 10, 12, 18, 34 Over the last few years 
TZDs have been studied in a number of trials, mostly to 
assess efficacy and durability of these drugs as well as 
their long-term outcomes and safety profile. TZDs are 
comparable to metformin and SU when it comes to 
glucose lowering, with an approximate HbA1c reduction 
of between -1.2% to -2.3% over a period of 3 to 12 
months.18, 22 They are not associated with increased risk 
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of hypoglycaemia and the A Diabetes Outcome 
Progression Trial (ADOPT), showed that rosiglitazone 
was associated with a lower cumulative incidence to 
monotherapy failure at 5 years then did metformin or 
glyburide suggesting that it had greater glycemic 
durability over the other drugs.22, 35 The most common 
side-effects of these drugs include weight gain, fluid 
retention leading to peripheral oedema as well as 
contributing to heart failure, effects on lipid profile as 
well as an associated increased risk of bone fractures in 
women in the long term.1, 22, 34 Weight gain is dose-
dependent and more pronounced when TZDs are used 
with insulin. With respect to their effect on lipid profile 
and other biochemical parameters, several studies have 
shown that TZDs are associated with an overall 
improved lipid profile with respect to HDL-C and TG, 
however in one study rosiglitazone was associated with 
significant increases in LDL-C.  Other improved 
cardiovascular parameters include a lowering of highly 
sensitive (hs)-CRP (anti-inflammatory effect) improved 
endothelial function and a reduction in procoagulatory 
state.18 The side effect of fluid retention with TZDs is 
widely recognised as is the associated consequence of 
heart failure, however, their effect on other 
cardiovascular end-points have been of much debate 
over the last few years. When looking at individual 
clinical trials as well as meta-analyses of RCT and 
observational studies with respect to cardiovascular 
events, studies on rosiglitazone seem to show an 
increased risk while studies on pioglitazone show a 
possible cardiovascular benefit.10, 36-40  Although the 
meta-analysis by Nissen and Wolski in 2007 showed 
that there was a significant increased risk of myocardial 
infarction, angina and cardiovascular mortality in 
patients taking rosiglitazone when compared with 
metformin, SU or placebo, this meta-analysis was 
heavily criticised for excluding studies with no relevant 
events and that some trials were too short to assess 
cardiovascular outcomes.10, 41 On the other hand the 
RECORD (rosiglitazone evaluated for cardiovascular 
outcomes in oral agent combination therapy for type 2 
diabetes) study (which was a multicentre, randomised, 
open-label non-inferiority trial) showed that 
rosiglitazone did not increase the risk of a composite end 
point of MACE when compared with SU or metformin, 
but it did not rule out an elevated risk of myocardial 
infarction.37, 42 The results of this study were also 
questioned partly in view of the open-label, unblinded 
design as well as concerns regarding data integrity 
which led to the FDA to ask for readjudication of the 
data. Following this, the results which emerged were 
reassuring that rosiglitazone was not associated with 
excess cardiovascular risk which eventually led the FDA 
in 2013 to remove  some of the prescribing and 
dispensing restrictions on rosiglitazone.15, 43 With respect 
to pioglitazone, several leading studies have shown a 
benefit of this drug on cardiovascular end-points.  The 
notable PROactive (PROspective pioglitazone Clinical 
Trial In macrovascular Events) randomised controlled 
study found that in patients with prior evidence of 
macrovascular disease, pioglitazone was associated with 
reduced risk of all-cause mortality, myocardial infarction 
(MI) and stroke.39 These differences on cardiovascular 
risk between pioglitazone and rosiglitazone are thought 
to be brought about by their differences on blood lipid 
profile – with pioglitazone having better effects on TG 
and HDL-C.6 However, the PROactive study did show 
an increase risk of oedema and congestive heart failure 
(CHF) in the pioglitazone treated groups when compared 
with placebo. An important feature not to be missed but 
is seen in most of the studies mentioned above is the fact 
that TZDs all have a decreased incidence of stroke.22  
With respect to fracture risk the ADOPT study showed 
an increased risk of distal bone fractures in women 
above the age of 60 with more fractures of the upper-
limb and foot rather than femoral neck or vertebrae thus 
stating that care should be taken when prescribing TZDs 
to female patients with regards to fracture risk.6 The fact 
that pioglitazone is both a PPAR-γ and α agonist, it has 
been linked to possibility of bladder cancer. A recent 
cohort study showed that short term use of pioglitazone 
was not associated with increased bladder cancer 
incidence, however increased risk is seen if treatment is 
given for more than 2 years.44 In light of all this one may 
wonder what is the place of these drugs in treatment 
strategies for patients with type 2 diabetes. Judicious use 
on an individualised basis should be the way forward 
with the hope that ongoing studies may shed more light 
and provide definitive answers.   
 
‘Glinides’ (Meglitinides) 
This class of antihyperglycaemic agents is also 
classified as insulin secretagogues, however they have a 
more rapid onset and shorter duration of action when 
compared to SU.  Their mode of action is similar to SU 
in that they also bind to the ATP-dependent K+ -channel 
on cell membranes of pancreatic β-cells, however they 
exert their actions via a different binding site.45 The fact 
that glinides have a short metabolic half-life (< 1 hour) 
with a fast onset of action makes them suitable as a 
prandial glucose regulators and hence ideal agents to 
cover the glucose load associated with meals.  Thus, 
repaglinide allows for flexibility of dosing such that if a 
meal is missed then so is the corresponding dose and this 
will in turn lead to a reduced risk of hypoglycaemia. One 
study on repaglinide assessed glycemic control after 
patients were randomised to treatment with either this 
drug or placebo. Use of  repaglinide was associated with 
significantly lower values of HbA1c, fasting and 
postprandial glucose (FPG, PPG) then placebo and at the 
end of the study there was a mean group difference in 
HbA1c of -1.7%. The commonest adverse event 
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encountered in both treatment groups was mild-to –
moderate hypoglycaemia with most of the events in the 
repaglinide treated group occurring during the dose-
adjustment period.45 In another study, repaglinide was 
administered to patients uncontrolled on metformin 
monotherapy. This led to significant reductions in 
HbA1C and FPG then when repaglinide or metformin 
were given on their own suggesting synergism when 
metformin is combined to repaglinide however, there 
was a significant increase in body weight with 
repaglinide use.46 Thus this agent appears to be an ideal 
component in managing type 2 diabetes as it has 
desirable characteristics which make it advantageous for 
use in certain patients such as the elderly (due to 
decreased risk of hypoglycaemia) or in patients with 
renal impairment due to its preferential metabolism in 
the liver.45 
 
α-glucosidase inhibitors 
This class of drugs suppresses glucose levels by 
preventing the digestion and absorption of complex gut 
carbohydrates (starch and sucrose) secondary to 
inhibition of intestinal α-glucosidase, thus lowering the 
post- prandial blood glucose level. These agents are used 
more infrequently nowadays, globally, mostly due to 
their renowned gastrointestinal side effects of flatulence 
and diarrhoea.1, 18, 22  They commonly reduce HbA1c by 
around -0.6 to -1.3% and are approved for use both as 
monotherapy and in combination with other anti 
hyperglycaemic drugs.18  With respect to weight, a 
Cochrane review stated that treatment with acarbose (the 
most commonly used α-glucosidase inhibitor) is 
associated with around -1.2kg weight loss in patients 
with prediabetes compared to placebo treatment. 
Furthermore there were nonsignificant ameliorations in 
serum lipid levels as well as BP.18 A commonly cited 
meta-analysis on acarbose (which included 7 placebo-
controlled RCTs) found that this drug was associated 
with reduced risk of ‘any cardiovascular event’ and also 
MI.47 Another RCT called the STOP-NIDDM assessed 
the effects of acarbose on development of frank diabetes 
in patients with impaired glucose tolerance.  Here the 
authors found that decreasing the post-prandial 
hyperglycaemia was associated with a 49% risk 
reduction in developing any cardiovascular event with 
the major reduction occurring in the risk of MI.  There 
was also a statistically significant reduction in BP, even 
though it must be acknowledged that there were a 
significant number of patients who discontinued 
treatment due to side-effects.48 However in a substudy of 
the UKPDS, patients randomised to acarbose did not 
have any significant differences on the risk of major 
clinical events.49 Thus, although there is no doubt about 
the benefits of acarbose on blood glucose lowering, data 
with respect to cardiovascular risk is still conflicting. 
Amylin analogues 
Amylin is a peptide hormone which is co-secreted 
with insulin from pancreatic β-cells following ingestion 
of nutrients of which secretion is either absent or 
diminished in diabetic patients.  Pramlintide, which is an 
amylin - receptor agonist is an equipotent synthetic 
analogue to amylin and has been approved for treatment 
of both type 1 and type 2 diabetes since 2005. It is 
thought to exert its glucose lowering effects by 
suppression of endogenous postprandial glucagon 
production leading to suppression of postprandial 
hepatic glucose production, by reducing gastric 
emptying time as well as induction of satiety through 
centrally mediated mechanisms leading to a reduction in 
postprandial glucose levels.1, 18, 50-51 Treatment with 
Pramlintide has proven to be efficacious in both type 1 
and 2 diabetes with beneficial effects on various 
metabolic parameters including HbA1c, weight and lipid 
levels. Since pramlintide is a peptide, it must be 
administered via the subcutaneous route (like insulin) to 
avoid degradation by gastrointestinal acids.   In type 2 
diabetes, it has been approved for use as adjunctive 
treatment to mealtime insulin in patients with or without 
concurrent use of SU and/or metformin in patients not 
achieving adequate glucose control. The observed 
reductions in HbA1c were around -0.6% and this was 
not accompanied by any increases in hypoglycaemia as 
well as proportionately lower total daily insulin doses in 
type 2 diabetics.50 With respect to weight, pramlintide 
was associated with significant reductions in weight (of 
around -0.5 to 1.4kg) despite reductions in HbA1c, with 
more pronounced weight loss occurring when baseline 
BMI > 40kg/m².8, 50  When it comes to its effect on 
biomarkers of cardiovascular disease further studies are 
need to elucidate the effect of pramlintide on the 
complications of diabetes. However, a study in type 2 
diabetics showed significant reductions in total and 
LDL-cholesterol compared with placebo, with the 
greatest reductions seen when pramlintide was used at 
the highest dose.18, 51 The side-effect profile of 
pramlintide includes nausea as well as vomiting and 
anorexia, however all these occur most frequently during 
initiation of therapy and tend to ease off with continued 
use.  There is also an increased risk of severe 
postprandial hypoglycaemia occurring within 3 hours of 
administration of pramlintide, and thus it is advisable for 
patients to increase the frequency of monitoring in order 
to detect hypoglycaemia.51  
 
Incretin based therapies 
The incretin system consists of gut hormones 
notably glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon like peptide-1 (GLP-1). GIP is 
synthesised in the enteroendocrine K cells of the 
proximal ileum whereas GLP-1 is released from the 
enteroendocrine L cells of the distal ileum and is rapidly 
inactivated by the enzyme didpeptidyl peptidase IV 
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within the circulation. However administration of a 
dipeptidyl peptidase IV inhibitor prevents degradation of 
this peptide hormone allowing it to have a more 
prolonged action.   It is thought that these hormones are 
responsible for the enhanced insulin secretion seen in the 
postprandial phase. However, in patients with type 2 
diabetes this incretin effect is either lost or blunted, with 
a more pronounced impairment in GLP-1 secretion.1-2, 16-
17, 52-53  Consequently the two available drugs in this 
category are thus the GLP-1 agonists and the DPP IV 
inhibitors.  Some studies have shown that the 
insulinotropic effects of GLP-1 are preserved, such that 
infusion of GLP-1 may completely normalize beta and 
alpha cell sensitivity to glucose leading to potential 
novel pharmacotherapy in patients with type 2 diabete.53  
 
Glucagon like peptide-1 receptor agonists (GLP-1 
RA) 
The most commonly available agents in this class 
are exenatide (twice daily), exenatide extended-release 
(once weekly) and liraglutide.  These agents are peptide 
hormones and thus need to be injected via the 
subcutaneous route. As already stated, GLP-1 analogues 
are responsible for the stimulation of insulin secretion 
which is regulated by the intracellular glucose level as 
well and also reduce glucagon secretion from the alpha-
cells leading to a robust HbA1c lowering of around 0.8-
2.0%. However GLP-1 RA are associated with other 
beneficial effects including a delay in gastric emptying 
as well as early satiety resulting in decreased oral intake 
which  may  explain the modest weight loss seen with 
this treatment. GLP-1 RA also exerts positive effects on 
β-cells, namely it enhances β-cell proliferation and is 
also capable of inhibiting β-cell apoptosis.2, 52, 54    
Looking at the cardiovascular effects of these drugs it is 
thought that GLP-1 RA exert beneficial effects on the 
cardiovascular system due to the presence of GLP-1 
receptors in the heart and this happens independent of 
glucose control. Studies have shown that administration 
of GLP-1 resulted in improvement in the ejection 
fraction and both global and regional wall indices in 
patients who had had an acute myocardial infarct with 
associated low left ventricular ejection fraction, and that 
exenatide treatment was associated with lower rates of 
CV disease event rates when compared with other 
agents.2, 52- 53 It is also well known that GLP-1 RA have a 
beneficial effect on the metabolic profile in type 2 
diabetics. Exenatide therapy led to reductions in total 
cholesterol and triglycerides as well as reductions in 
systolic and diastolic blood pressure after 16 weeks of 
therapy.2, 18, 52 With respect to weight loss all studies 
report a positive effect of GLP-1RA on weight with a 
reduction in BMI by around – 0.44kg/m² when 
compared to placebo or insulin therapy.54-55 With respect 
to adverse effects, GLP-1R analogues have been 
associated with lower risk for hypoglycaemia when 
administered as monotherapy or when compared to 
insulin.52, 55-56 Other adverse side effects include an 
increased incidence of gastrointestinal effects including 
nausea, vomiting and diarrhoea when compared to 
placebo or insulin therapy.52, 54-55 Regarding  long term 
cardiovascular outcome studies, one meta- analysis did 
not find any evidence to suggest an increase in 
cardiovascular morbidity when compared to placebo or 
other drugs.57 There have been reports of short-term risk 
of acute pancreatitis as well as potential for long-term 
risk of chronic pancreatitis in patients taking this class of 
drugs, however, patients had other potential causes for 
this and the data available to date does not convincingly 
prove this risk. Even so, the FDA asks for vigilance 
when prescribing these drugs to patients and to report 
any such cases.58 Concerns have also been raised on 
GLP-1R analogues with regards to their propensity to 
cause proliferative changes in rodent thyroid C cells 
including C-cell hyperplasia, adenomas, and medullary 
thyroid carcinomas although data in human subjects did 
not show any elevations in serum calcitonin levels and 
there have been no case reports describing medullary 
thyroid carcinomas in patients receiving GLP-1R agonist 
treatment.  However more long term trials need to be 
available concerning the above issues as till now the data 
is not robust enough.52  Finally there is limited data with 
respect to mortality with GLP-1 analogues, however 
studies to date suggests that there is no increased risk 
during treatment with such drugs.59 
 
Dipeptidyl peptidase-4 (DPP-4) Inhibitors 
This class of drugs are also part of the incretin 
system of gut hormones. These work by preventing 
breakdown of endogenous GLP-1 and GIP leading to 
enhanced circulating concentrations of these hormones 
which in turn lead to glucose dependent insulin secretion 
as well as inhibition of glucagon secretion. The four 
widely available agents are all orally active and include 
sitagliptin, vildagliptin, saxagliptin and linagliptin.1-2, 18, 
22, 52, 60 Studies have shown that these drugs are generally 
well tolerated, reduce HbA1c by around -0.8% are 
weight neutral and by themselves are not associated with 
hypoglycaemia, thus the FDA has  approved them for 
both monotherapy as well as in combination with other 
anti-hyperglycaemic drugs in the treatment of type 2 
diabetic patients.1, 18, 52, 58, 60 Their pharmacodynamic and 
pharmacokinetic properties are what make DPP-4 
inhibitors attractive for use especially in certain groups 
of people.  The fact that they cause glucose dependent 
insulin secretion and thus decreased risk of 
hypoglycaemia when compared to SU, as well as the 
fact that saxagliptin and vildagliptin are metabolised by 
the liver implies that they may be used in elderly 
patients or patients with renal failure. They also enjoy 
good overall tolerability (when compared with 
metformin they are associated with lower 
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gastrointestinal adverse effects) and are not associated 
with the weight gain seen with SU and TZD use.18, 22, 59, 
61  Moreover they are also associated with positive 
effects on surrogate parameters of cardiovascular risk.  
Studies have shown a favourable trend with regard to 
triglyceride, HDL-C and LDL-C levels52-53 and emerging 
data from recent studies and meta-analysis also show 
that DPP-4 inhibitors have a positive effect on the 
cardiovascular system.  One study has shown that 
administration of sitagliptin to patients with coronary 
artery disease led to increased ejection fraction and 
improved contractile function of the ischemic areas.62 
Also, it has been shown that DPP-4 inhibitors reduce 
blood pressure in a number of studies and in animal 
studies gliptins seem to exert a positive effect on the 
evolution of heart failure which was independent of 
blood glucose control.63 When looking at the effects of 
DPP-4 inhibitors on cardiovascular events two recent 
meta-analyses state that DPP-4 inhibitor reduce the risk 
of major adverse cardiovascular events – in particular 
myocardial infarction as well as decreased all-cause 
mortality and are thus reported as having a safe profile 
from a cardiovascular standpoint which is not seen with 
certain other anti-hyperglycaemic agents.64-66  Several 
other large-scale trials are in the making specifically 
designed to assess the cardiovascular effects of each 
gliptin.  One such study, the SAVOR-TIMI 53, has 
recently published data which states that saxagliptin 
found no excess or reduction in rates of ischemic events. 
It was noted, however that patients randomised to the 
saxagliptin arm had increased rates of hospitalisation for 
heart failure, which warrants further investigation.67 
With respect to the association of DPP-4 inhibitors with 
the risk of pancreatitis, pancreatic cancer and C-cell 
proliferation, data is very minimal and not uniformly 
reproducible in human studies thus further data is 
required in this area.59  Thus the literature available 
implies that these novel drugs are proving to be pivotal 
in the treatment of type 2 diabetes, and that the benefits 
of DPP-4 inhibitor therapy by far outweigh the risks, 
making them key agents in the therapeutic 
armamentarium for type 2 diabetes.  
      
Insulins 
Insulin is the mainstay of treatment in type 1 
diabetes and is an option in type 2 diabetes when other 
hypoglycaemic agents fail to maintain adequate blood 
glucose levels.16-17, 34, 52, 58 With respect to other 
antihyperglycemic agents, insulin delivers superior 
glucose reductions and this is consolidated by the fact 
that it offers up to 4.9% reductions in HbA1c levels.18  
There are various different types of insulins available 
depending either on the source (animal, human or 
analogue insulins) or their action profile (short-, 
intermediate- and long-acting insulins).17 Short acting 
insulins include those with a rapid onset and short 
duration of action such as soluble insulin (Humulin S®) 
or the newer analogues (such as aspart or gluisine) and 
notably these are used to cover prandial glucose 
excursions.16-17, 52  Intermediate acting insulin such as 
isophane insulin (neutral protamine Hagerdon [NPH] 
has an onset of action within 1-2 hours and lasts for 
around 8-14 hours whereas long acting insulins (notably 
the analogues glargine or detemir) have a longer 
duration of action of around 22-24 hours and provides a 
consistent release of insulin during the day reminiscent 
of natural basal insulin release without any peaks of 
activity.68-69 Insulin therapy in type 2 diabetes can be 
administered in different ways.  Usually, insulin 
initiation takes the form of bedtime insulin using either 
isophane insulin or a once daily long-acting insulin 
analogue (such as glargine) and step-up treatment with 
either bi-daily injection of premixed biphasic insulin or 
short-acting insulin before meals (in a basal –bolus 
fashion) occurring if adequate glucose control is still not 
achieved.34, 52 In the United Kingdom Prospective 
Diabetes Study (UKPDS) tight glycemic control with a 
combination of insulin and oral hypoglycaemic agents 
was associated with lower HbA1c values then those in 
the conventionally treated group and also had 
significantly decreased risk of microvascular 
complications, and furthermore, in the 10 year post trial 
follow up there was also a significant reduction in 
myocardial infarctions thus implying that insulin use is 
indispensable in type 2 diabetes and is also effective at 
preventing onset of complications.  However, these 
results came at the expense of an increase in the rate of 
both hypoglycaemia and weight gain.20-21, 69-70  With the 
development of long acting insulin analogues there is an 
improvement the insulin profile such that when injected 
subcutaneously there is a constant release of insulin into 
the bloodstream and without any peaks in insulin 
concentration over 24 hours (as opposed to isophane 
insulin) thus providing the basal component in the basal-
bolus regime with the added benefit of once daily 
dosing.69, 71 Thus, these inherent pharmacokinetic and 
pharmacodynamic properties of insulin analogues have 
been thought to be responsible for the decreased risk of 
hypoglycaemia especially nocturnal hypoglycaemia.69, 71 
Several studies have shown that long-acting insulin 
analogues achieve comparable glucose control to NPH 
insulin with lower rates of symptomatic and nocturnal 
hypoglycaemia with detemir also showing significantly 
less weight gain.34, 68-69, 72-73 With respect to long term 
outcome trials, in the 10-year post-trial follow-up of the 
UKPDS, patients subjected to an intensive treatment 
regime continued to show a reduction in microvascular 
risk by 15% as well as reductions for any diabetes-
related end point and death from any cause (9% and 
13% respectively) even though the differences in HbA1c 
levels attained were lost after the first year.  This 
‘legacy-effect’ implies that early aggressive glycemic 
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control is associated with a sustained reduction in 
microvascular risk and in any diabetes-related end point. 
Furthermore, there was also a significant reduction in 
risk of either myocardial infarction or death from any 
cause which was not seen during the interventional 
phase of the trial.18, 21 Finally, the UKPDS also 
investigated the concerns that exogenous insulin may 
potentially be harmful by enhancing atheroma formation 
due to the high insulin concentrations. This was 
unproven in the study since patients assigned to 
intensive insulin treatment did not have an increase in 
myocardial infarctions suggesting that inherent treatment 
with insulin did not pose a cardiovascular risk.20  There 
have also been insinuations that high concentrations of 
insulin and thus increased binding of insulin to IGF-1 
receptors may promote tumorigenesis. Insulin glargine 
has increased potency at the IGF-1 receptor then regular 
human insulin, however studies in rats and mice as well 
as a recent review of glargine-treated patients did not 
support an increased risk of carcinogenicity.69- 70   
 
Conclusion 
Thus as one can see the clinician has at his disposal 
a number of antihyperglycemic agents available for the 
management of hyperglycemia.  As with all chronic 
medical conditions an individualised approach within a 
comprehensive care framework should be the way 
forward with many regulatory bodies advocating 
pharmacotherapy to be used as an adjunct to lifestyle 
modification.  It is now universally acknowledged that 
management of diabetes does not only involve lowering 
of blood glucose but also the management of other 
cardiometabolic parameters such as serum lipid levels, 
blood pressure and platelet aggregation which have all 
been associated with adverse cardiovascular events.  It is 
understood that most patients will eventually require 
more than one antihyperglycemic agent for optimum 
control of their diabetes, and thus the risks and benefits 
of each drug should be considered when prescribing a 
treatment regime as should the individual patient 
characteristics (such as age, weight, presence of 
comorbidities, risk of hypoglycaemia and so forth) in 
order to be successful at achieving optimum glycemic 
control without the occurrence of undesirable effects. 
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